Phase ii study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B- And T-cell non-Hodgkin lymphomas
Jonathan W. Friedberg, Daruka Mahadevan, Erin Cebula, Daniel Persky, Izidore Lossos, Amit B. Agarwal, Jung Ah Jung, Richard Burack, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, Hadi Danaee, Steven H. Bernstein
Producción científica: Article › revisión exhaustiva
Profundice en los temas de investigación de 'Phase ii study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B- And T-cell non-Hodgkin lymphomas'. En conjunto forman una huella única.